Cilostazol

Generic Name: Cilostazol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Associated Therapies: -

Clinical Trials

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Not Applicable

Completed

Conditions: Migraine Without Aura
Migraine Headache

Interventions: Drug: Feraheme
Drug: Cilostazol
Other: USPIO-MRI
Other: BBI-MRI

First Posted Date: 2015-09-15

Last Posted Date: 2022-07-27

Lead Sponsor: Danish Headache Center

Target Recruit Count: 34

Registration Number: NCT02549898

Locations: 🇩🇰
Rigshospitalet Glostrup, Glostrup, Denmark

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2

Completed

Conditions: Mild Cognitive Impairment

Interventions: Drug: Placebo
Drug: Cilostazol

First Posted Date: 2015-07-08

Last Posted Date: 2020-12-04

Lead Sponsor: National Cerebral and Cardiovascular Center, Japan

Target Recruit Count: 166

Registration Number: NCT02491268

Locations: 🇯🇵
National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Not Applicable

Completed

Conditions: Migraine

Interventions: Drug: Cilostazol
Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2015-07-01

Last Posted Date: 2017-05-09

Lead Sponsor: Danish Headache Center

Target Recruit Count: 30

Registration Number: NCT02486276

Locations: 🇩🇰
Emma Katrine Hansen, Copenhagen, Glostrup, Denmark

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Phase 4

Conditions: Brain Ischemia
Intracranial Hemorrhages

Interventions: Drug: cilostazol
Drug: Probucol
Drug: Aspirin
Drug: Placebo of aspirin
Drug: placebo of cilostazol
Device: Intima-medial thickness

First Posted Date: 2015-06-26

Last Posted Date: 2015-12-24

Lead Sponsor: Asan Medical Center

Target Recruit Count: 800

Registration Number: NCT02483169

Lacunar Intervention Trial 1 (LACI-1)

Phase 2

Completed

Conditions: Cerebral Small Vessel Diseases
Cognitive Impairment
Stroke

Interventions: Drug: isosorbide mononitrate
Drug: cilostazol

First Posted Date: 2015-06-25

Last Posted Date: 2018-01-19

Lead Sponsor: University of Edinburgh

Target Recruit Count: 57

Registration Number: NCT02481323

Locations: 🇬🇧
University of Edinburgh, Edinburgh, United Kingdom
🇬🇧
University of Nottingham, Nottingham, United Kingdom

Cilostazol-Simvastatin Drug Interaction Study

Phase 1

Conditions: Dyslipidemias
Peripheral Artery Disease

Interventions: Drug: Simvastatin
Drug: Pravastatin
Drug: Cilostazol

First Posted Date: 2015-04-30

Last Posted Date: 2015-05-01

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 20

Registration Number: NCT02431013

Locations: 🇰🇷
Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of

Cilostazol After Lower Extremity Arterial Revascularization Trial

Phase 4

Terminated

Conditions: Peripheral Arterial Disease
Claudication (Finding)

Interventions: Drug: Cilostazol

First Posted Date: 2015-03-02

Last Posted Date: 2018-11-23

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 20

Registration Number: NCT02374957

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Cilostazol
Drug: Aspirin

First Posted Date: 2014-10-16

Last Posted Date: 2017-10-09

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 100

Registration Number: NCT02266030

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Bundang-gu, Korea, Republic of

Induction of Migraine Aura With Cilostazol

Early Phase 1

Completed

Conditions: Migraine With Aura
Stroke

Interventions: Drug: Placebo
Drug: Cilostazol

First Posted Date: 2014-10-01

Last Posted Date: 2015-08-21

Lead Sponsor: Herlev Hospital

Target Recruit Count: 16

Registration Number: NCT02253004

Locations: 🇩🇰
Herlev Hospital, Dept Neurology, Herlev, Denmark

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease

Phase 4

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Dummy Placebo
Drug: Cilostazol

First Posted Date: 2014-07-18

Last Posted Date: 2015-10-14

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 71

Registration Number: NCT02194686

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy